Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Rare Tumour × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 434 Neoplasms 348 Carcinoma, Non-Small-Cell Lung 265 Colorectal Neoplasms 232 Lung Neoplasms 201 Prostatic Neoplasms 186 Carcinoma, Hepatocellular 163 Stomach Neoplasms 137 Multiple Myeloma 121 Pancreatic Neoplasms 115 Uterine Cervical Neoplasms 100 Leukemia, Myeloid, Acute 100 Rectal Neoplasms 99 Ovarian Neoplasms 90 Recurrence 89 Squamous Cell Carcinoma of Head and Neck 85 Neoplasm Metastasis 80 Glioblastoma 76 Head and Neck Neoplasms 73 Small Cell Lung Carcinoma 71 Esophageal Neoplasms 68 Endometrial Neoplasms 67 Brain Neoplasms 67 Triple Negative Breast Neoplasms 62 Colonic Neoplasms 62 Glioma 58 Precursor Cell Lymphoblastic Leukemia-Lymphoma 57 Hematologic Neoplasms 52 Urinary Bladder Neoplasms 51 Motor Activity 51

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡